Literature DB >> 9521568

Simultaneous measurement of venlafaxine and its major metabolite, oxydesmethylvenlafaxine, in human plasma by high-performance liquid chromatography with coulometric detection and utilisation of solid-phase extraction.

E M Clement1, J Odontiadis, M Franklin.   

Abstract

Venlafaxine, oxydesmethylvenlafaxine and an internal standard (paroxetine) were extracted from plasma by a solid-phase extraction technique. Chromatography was performed using isocratic reversed-phase high-performance liquid chromatography (HPLC) with coulometric endpoint detection. The standard curves were linear over the range 0-200 ng/ml for both venlafaxine and oxydesmethylvenlafaxine in plasma. The mean inter- and intra-assay coefficients of variation over the range of the standard curves were less than 10%. The absolute recovery averaged 74% for venlafaxine and 67% for oxydesmethylvenlafaxine. The sensitivity was 0.5 ng for both the analytes. Plasma profiles of the analytes following oral administration of venlafaxine, are presented.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521568     DOI: 10.1016/s0378-4347(97)00524-0

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  8 in total

1.  Sensitive spectrofluorimetric method of analysis for venlafaxine in spiked rat plasma and formulations.

Authors:  Sheikh Shahnawaz; Zaki Siddiqui; Quaisul Hoda
Journal:  J Fluoresc       Date:  2010-02-27       Impact factor: 2.217

2.  RP-HPLC Estimation of Venlafaxine Hydrochloride in Tablet Dosage Forms.

Authors:  S L Baldania; K K Bhatt; R S Mehta; D A Shah; Tejal R Gandhi
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

3.  Paroxetine treatment and the prolactin response to sumatriptan.

Authors:  Y K Wing; E M Clifford; B D Sheehan; G M Campling; R A Hockney; P J Cowen
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

4.  Development and validation of an ultra performance liquid chromatography method for venlafaxine hydrochloride in bulk and capsule dosage form.

Authors:  U K Chhalotiya; H B Patel; K K Bhatt
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

5.  Development and validation of stability indicating method for the quantitative determination of venlafaxine hydrochloride in extended release formulation using high performance liquid chromatography.

Authors:  Jaspreet Kaur; K K Srinivasan; Alex Joseph; Abhishek Gupta; Yogendra Singh; Kona S Srinivas; Garima Jain
Journal:  J Pharm Bioallied Sci       Date:  2010-01

6.  Pharmacokinetics of venlafaxine and its major metabolite o-desmethylvenlafaxine in freely moving mice using automated dosing/sampling system.

Authors:  Bijay Aryal; Dipendra Aryal; Eun-Joo Kim; Hyung-Gun Kim
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

7.  Development and validation of a rapid HPLC- fluorescence method for simultaneous determination of venlafaxine and its major metabolites in human plasma.

Authors:  Y H Ardakani; A Foroumadi; M R Rouini
Journal:  Daru       Date:  2010       Impact factor: 3.117

8.  Rapid sensitive validated UPLC-MS method for determination of venlafaxine and its metabolite in rat plasma: Application to pharmacokinetic study.

Authors:  Sunil Kumar Dubey; R N Saha; Hemanth Jangala; S Pasha
Journal:  J Pharm Anal       Date:  2013-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.